We have qualitatively reviewed this strategy and reaffirmed its Process and People ratings. Vanguard Capital Opportunity stands out for its seasoned management and high-conviction multimanager system. The remainder of this analysis is from July 7, 2023.
Vanguard Capital Opportunity Inv VHCOX
- NAV / 1-Day Return 88.88 / −0.44 %
- Total Assets 23.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.430%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Large Growth
- Investment Style Large Growth
- Min. Initial Investment 3,000
- Status Limited
- TTM Yield 0.60%
- Turnover 6%
USD | NAV as of Oct 07, 2024 | 1-Day Return as of Oct 07, 2024, 10:56 PM GMT+0
Morningstar’s Analysis VHCOX
Will VHCOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 33.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 12.02 | 2.8 Bil | Healthcare |
Amgen Inc | 2.87 | 664.2 Mil | Healthcare |
Micron Technology Inc | 2.85 | 660.1 Mil | Technology |
Microsoft Corp | 2.67 | 618.3 Mil | Technology |
KLA Corp | 2.56 | 592.9 Mil | Technology |
Biogen Inc | 2.34 | 543.6 Mil | Healthcare |
FedEx Corp | 2.13 | 494.5 Mil | Industrials |
Mktliq 12/31/2049 | 2.12 | 491.1 Mil | Cash and Equivalents |
NVIDIA Corp | 1.99 | 461.4 Mil | Technology |
Biomarin Pharmaceutical Inc | 1.95 | 451.7 Mil | Healthcare |